Stockreport

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma [Yahoo! Finance]

Shuttle Pharmaceuticals Holdings, Inc.  (SHPH) 
PDF Food and Drug Administration (FDA) for the Company's investigational new drug (IND) application for its Phase II study of Ropidoxuridine (IPdR) as a radiation sensitizin [Read more]